The ingredient is marketed as a safer, more effective alternative to caffeine.
TSI Group (Missoula, MT) has gained exclusive distribution rights for Enfinity Energy LLC’s Enfinity ingredient, which is said to be a safer, more effective alternative to caffeine. According to the companies, “Enfinity functions more consistently than caffeine, leading to fewer side effects, greater enjoyability, improved mood, and a more focused mindset.”
Enfinity is made of paraxanthine. As the companies explain, “Roughly 70% of caffeine is metabolized as paraxanthine, which is caffeine’s efficacious compound. Enfinity bypasses the side effect–riddled middlemen (theophylline, theobromine, and caffeine itself) and goes straight to work delivering newfound energy without jitters, anxiety, crashes, or sleep problems.”
Enfinity’s benefits include providing energy, focus, and “wakeful clarity”; enhancing mood and well-being; acting as a neuroprotective cognitive accelerant; improving reaction time and reducing mental errors; and increasing caloric expenditure and thermogenesis.
The ingredient is also said to be easier to formulate with compared to caffeine because its taste is less bitter. It is suited for use in gummies, ready-to-drink beverages, energy drinks, fat burners, nootropics, and preworkout powders at a daily dose ranging from 100-300 mg.
The ingredient, which is supported by 23 filed patents, four human clinical studies, and more preclinical work, is now set to market globally under TSI’s distribution. Said TSI Group President Larry Kolb, “Enfinity is becoming very popular. It is a well-developed ingredient that is disrupting the industry with real innovation that has not been seen in years.”
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.